Cargando…
Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review
BACKGROUND: Selective estrogen receptor modulators, such as tamoxifen, reduce breast cancer risk by up to 50% in women at increased risk for breast cancer. Despite tamoxifen’s well-established efficacy, many studies show that most women are not taking up tamoxifen. This systematic literature review...
Autores principales: | Meiser, B., Wong, W. K. T., Peate, M., Julian-Reynier, C., Kirk, J., Mitchell, G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607482/ https://www.ncbi.nlm.nih.gov/pubmed/28943990 http://dx.doi.org/10.1186/s13053-017-0075-8 |
Ejemplares similares
-
Are women at high risk for serous gynaecological cancer (SGC) opting for risk-reducing salphingo-oophorectomy motivated by high levels of anxiety and risk perceptions?
por: Meiser, B, et al.
Publicado: (2012) -
Tamoxifen for women at high risk of breast cancer
por: Nazarali, Safia A, et al.
Publicado: (2014) -
Tamoxifen reduces plasma homocysteine levels in healthy women.
por: Cattaneo, M., et al.
Publicado: (1998) -
Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.
por: Jones, A. L., et al.
Publicado: (1992) -
Magnitude and attributed reasons for adult weight gain amongst women at increased risk of breast cancer
por: Pegington, Mary, et al.
Publicado: (2022)